Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art
Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Gluco...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Emergency Department of Hospital San Pedro (Logroño, Spain)
2023-02-01
|
| Series: | Iberoamerican Journal of Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.53986/ibjm.2023.0009 |
| _version_ | 1797845427235586048 |
|---|---|
| author | Yilmar Alexader Meza-González Natalia Alfonso-Arrieta Stephany Salas-Solorzano Victor Florez-Garcia |
| author_facet | Yilmar Alexader Meza-González Natalia Alfonso-Arrieta Stephany Salas-Solorzano Victor Florez-Garcia |
| author_sort | Yilmar Alexader Meza-González |
| collection | DOAJ |
| description | Heart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2 Inhibitors) initially entered the market to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM), however the discovery of the cardiovascular benefits in patients with HF, regardless of the presence or absence of T2DM positioned it as a new pillar in clinical management.
In this state-of-the-art review resulting from a comprehensive literature search (Medline, Cochrane and EMBASE), we describe the impact of SGLT2 Inhibitors on mortality and rehospitalizations in patients with HF and we propose a therapeutic plan for patients with HF to maximizes the benefits. |
| first_indexed | 2024-04-09T17:38:50Z |
| format | Article |
| id | doaj.art-c21a344aafa441deab46631c9e0d66a2 |
| institution | Directory Open Access Journal |
| issn | 2695-5075 |
| language | English |
| last_indexed | 2024-04-09T17:38:50Z |
| publishDate | 2023-02-01 |
| publisher | Emergency Department of Hospital San Pedro (Logroño, Spain) |
| record_format | Article |
| series | Iberoamerican Journal of Medicine |
| spelling | doaj.art-c21a344aafa441deab46631c9e0d66a22023-04-17T09:11:26ZengEmergency Department of Hospital San Pedro (Logroño, Spain)Iberoamerican Journal of Medicine2695-50752023-02-01526877https://doi.org/10.53986/ibjm.2023.0009Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the ArtYilmar Alexader Meza-González0https://orcid.org/0000-0003-2731-1135Natalia Alfonso-Arrieta1Stephany Salas-Solorzano2Victor Florez-Garcia3Department of Internal Medicine. Universidad del Norte. Barranquilla, ColombiaDepartment of Internal Medicine. Universidad del Norte. Barranquilla, ColombiaDepartment of Internal Medicine. Universidad del Norte. Barranquilla, ColombiaJoseph J. Zilber School of Public Health, University of Wisconsin, Milwaukee, United States of AmericaHeart Failure (HF) is a cardiovascular condition with high morbidity and mortality that conditions one of the most critical problems in public health. Despite advances in recent decades, patients continue to have major cardiovascular events and marked reduction in their quality of life. Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2 Inhibitors) initially entered the market to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM), however the discovery of the cardiovascular benefits in patients with HF, regardless of the presence or absence of T2DM positioned it as a new pillar in clinical management. In this state-of-the-art review resulting from a comprehensive literature search (Medline, Cochrane and EMBASE), we describe the impact of SGLT2 Inhibitors on mortality and rehospitalizations in patients with HF and we propose a therapeutic plan for patients with HF to maximizes the benefits.https://doi.org/10.53986/ibjm.2023.0009heart failuresglt2 inhibitorsnephroprotectiontype 2 diabetes mellitus |
| spellingShingle | Yilmar Alexader Meza-González Natalia Alfonso-Arrieta Stephany Salas-Solorzano Victor Florez-Garcia Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art Iberoamerican Journal of Medicine heart failure sglt2 inhibitors nephroprotection type 2 diabetes mellitus |
| title | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art |
| title_full | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art |
| title_fullStr | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art |
| title_full_unstemmed | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art |
| title_short | Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art |
| title_sort | sodium glucose co transporter type 2 inhibitors and heart failure a review of the state of the art |
| topic | heart failure sglt2 inhibitors nephroprotection type 2 diabetes mellitus |
| url | https://doi.org/10.53986/ibjm.2023.0009 |
| work_keys_str_mv | AT yilmaralexadermezagonzalez sodiumglucosecotransportertype2inhibitorsandheartfailureareviewofthestateoftheart AT nataliaalfonsoarrieta sodiumglucosecotransportertype2inhibitorsandheartfailureareviewofthestateoftheart AT stephanysalassolorzano sodiumglucosecotransportertype2inhibitorsandheartfailureareviewofthestateoftheart AT victorflorezgarcia sodiumglucosecotransportertype2inhibitorsandheartfailureareviewofthestateoftheart |